GB2546703A - Compounds - Google Patents

Compounds

Info

Publication number
GB2546703A
GB2546703A GB1707536.7A GB201707536A GB2546703A GB 2546703 A GB2546703 A GB 2546703A GB 201707536 A GB201707536 A GB 201707536A GB 2546703 A GB2546703 A GB 2546703A
Authority
GB
United Kingdom
Prior art keywords
compounds
arsenosugar
arsenobetaine
analogues
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1707536.7A
Other versions
GB201707536D0 (en
Inventor
Iqbal Haris Parvez
Owen Jenkins Richard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
De Montfort University
Original Assignee
De Montfort University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Montfort University filed Critical De Montfort University
Publication of GB201707536D0 publication Critical patent/GB201707536D0/en
Publication of GB2546703A publication Critical patent/GB2546703A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to arsenic compounds, particularly arsenobetaine and arsenosugar analogues and derivatives and their use in therapy, particularly for the prevention and/or treatment of cancer.
GB1707536.7A 2014-10-17 2015-10-16 Compounds Withdrawn GB2546703A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1418491.5A GB201418491D0 (en) 2014-10-17 2014-10-17 Compounds
PCT/EP2015/073974 WO2016059198A1 (en) 2014-10-17 2015-10-16 Compounds

Publications (2)

Publication Number Publication Date
GB201707536D0 GB201707536D0 (en) 2017-06-28
GB2546703A true GB2546703A (en) 2017-07-26

Family

ID=52013185

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1418491.5A Ceased GB201418491D0 (en) 2014-10-17 2014-10-17 Compounds
GB1707536.7A Withdrawn GB2546703A (en) 2014-10-17 2015-10-16 Compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1418491.5A Ceased GB201418491D0 (en) 2014-10-17 2014-10-17 Compounds

Country Status (2)

Country Link
GB (2) GB201418491D0 (en)
WO (1) WO2016059198A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020048A2 (en) * 2004-07-16 2006-02-23 The Texas A & M University System Compounds and methods for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020048A2 (en) * 2004-07-16 2006-02-23 The Texas A & M University System Compounds and methods for treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells", A.H. Van der Luit et al, Molecular Cancer Therapeutics, (2007), 6(8), 2337-2345 *
"Modulation of cell adhesion and viability of cultured murine bone marrow cells by arsenobetaine, a major organic arsenic compound in marine animals", T. Sakurai et al, British Journal of Pharmacology, 132(1), (2001), 143-150 *
"Novel therapeutic approach: Organic arsenical (melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo", K. Koshiuka et al, British Journal of Cancer, (2000), 82(2), 452-458 *

Also Published As

Publication number Publication date
GB201707536D0 (en) 2017-06-28
WO2016059198A1 (en) 2016-04-21
GB201418491D0 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
MY187540A (en) Compounds active towards bromodomains
IL256224B (en) Combination therapy for the treatment of cancer
TW201613901A (en) New compounds
GB2541571A (en) Pharmaceutical compositions
IL258521A (en) Combination therapy for the treatment of cancer
IL276733A (en) Use of eribulin in the treatment of cancer
MX2018000715A (en) Methods for treating cancer using apilimod.
MX2016014559A (en) Compounds for treatment of cancer.
MX2017002489A (en) Human therapeutic agents.
MX2019005349A (en) Use of sanglifehrin macrocyclic analogues as anticancer compounds.
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
MX370412B (en) Antimycotic compound.
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
IL247586A0 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
PH12016501838A1 (en) Compounds and their methods of use
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
IL269121A (en) Usl-311 for use in the treatment of cancer
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
GB2546703A (en) Compounds
PH12017501063A1 (en) Compounds for the treatment of cancer
MX2019003002A (en) Combination therapies using indazolylbenzamide derivatives for the treatment of cancer.
MX2018013863A (en) Combination therapies using indazolylbenzamide derivatives for the treatment of cancer.

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)